Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax.

The letter to the editor discusses the successful treatment of acquired von Willebrand syndrome (AVWS) secondary to low-grade chronic lymphocytic leukemia (CLL) using rituximab and venetoclax. AVWS is a condition characterized by defects in von Willebrand factor that can arise from various non-heritable pathogenic processes. The case study presented in the letter highlights the resolution of AVWS with rituximab and venetoclax combination therapy, emphasizing the importance of recognizing and treating AVWS in the context of underlying lymphoproliferative disorders like CLL. The treatment regimen was well-tolerated and led to a durable remission of AVWS, showcasing the potential effectiveness of new CLL regimens for managing AVWS secondary to lymphoproliferative diseases. [Extracted from the article]